POEMS syndrome

The acronym refers to polyneuropathy, organ enlargement, endocrine problems, a monoclonal protein and skin changes. Diagnosis does not require every feature in the acronym, but it does require a specific combination of findings including neuropathy and a monoclonal plasma-cell disorder.

Other important features can include sclerotic bone lesions, fluid accumulation, raised platelets and an elevated vascular endothelial growth factor (VEGF) level. VEGF is useful in assessment and monitoring, but no single blood result diagnoses POEMS on its own.

An abnormal plasma-cell clone and altered signaling proteins contribute to the syndrome. The underlying mechanism is not fully understood, and the reason a person develops it is usually unknown.

POEMS is not contagious and is not simply the same disease as conventional multiple myeloma. The plasma-cell burden can be small while nerve and organ symptoms are substantial.

Peripheral neuropathy commonly causes numbness, pain, weakness and problems walking. Hormonal abnormalities, skin changes, an enlarged liver or spleen and fluid retention can affect daily life.

Breathing and circulation can also be affected. Neurological recovery can be slow, so reduced plasma-cell activity and a lower VEGF level do not mean that strength or sensation will immediately return.

Radiotherapy can treat localized disease driven by one or a few suitable bone lesions when there is no disseminated marrow involvement. The extent of the clone is therefore important in deciding whether local or systemic treatment is needed.

Systemic disease is treated with plasma-cell-directed medicines. High-dose melphalan followed by autologous stem cell rescue is an established option for appropriately selected patients. Organ function, fluid overload, pulmonary problems and functional status affect transplant planning.

Other drug combinations can be used when transplant is unsuitable or as part of a treatment sequence. Pre-existing neuropathy can influence medicine selection. Rehabilitation, pain management, endocrine treatment and support for affected organs are needed alongside control of the clone.

Mobility problems may persist during recovery even when tests show a treatment response. Physical and occupational therapy, walking aids and help with everyday tasks can be important parts of the plan.

Autologous transplantation can cause temporary blood-count suppression and infection risk. POEMS also requires attention to fluid and inflammatory complications around engraftment. Follow-up tracks both the plasma-cell disorder and functional improvement over time.

The transplant used for POEMS is usually autologous: the person’s own blood-forming cells are collected and returned after high-dose chemotherapy. It does not replace damaged nerves with donor cells.

An unrelated registry donor is not part of the usual POEMS treatment pathway, and allogeneic transplantation is not routine. Registry recruitment supports people with other conditions who do need donated cells.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?